Results 21 to 30 of about 2,205,036 (277)
Treatment of hepatorenal syndrome [PDF]
Vojnosanitetski Pregled, 2007 <zakljucak> Hepatorenalni sindrom je funkcionalna insuficijencija bubrega u sklopu terminalne insuficijencije jetre. U patogenezi ovog sindroma ucestvuju hemodinamske promene (snizeni srednji arterijski pritisak i perfuzioni pritisak bubrega) i povecano stvaranje sistemskih i bubreznih vazoaktivnih medijatora sa stimulacijom bubreznog simpatickog
Kezić Aleksandra +2 more
doaj +3 more sources
Hepatorenal syndrome: an update [PDF]
São Paulo Medical Journal, 2007 Hepatorenal syndrome (HRS) is the development of renal failure in patients with chronic previous liver disease, without clinical or laboratory evidence of previous kidney disease.
Tércio Genzini +1 more
doaj +5 more sources
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [PDF]
, 2007 Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its
Francesco Salerno +4 more
openalex +7 more sources
Hepatology Communications, 2023 Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated with rapidly deteriorating kidney function.
M. Curry +5 more
semanticscholar +1 more source
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
New England Journal of Medicine, 2021 BACKGROUND The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. METHODS We conducted a phase 3 trial to confirm the efficacy and safety of
F. Wong +15 more
semanticscholar +1 more source
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Hepatology, EarlyView., 2022 Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran +17 more
wiley +1 more source
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
Kidney360, 2023 Key Points Hepatorenal syndrome type 1 (HRS-1) is an often fatal, but potentially reversible, kidney failure in patients with decompensated cirrhosis. Treatment with terlipressin in patients with HRS-1 is associated with a reduction in the need for RRT ...
J. Velez +8 more
semanticscholar +1 more source
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
Hepatology, EarlyView., 2022 The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck +14 more
wiley +1 more source